Alemtuzumab for haematological malignancies

Area of Science:

• Immunology
• Oncology
• Pharmacology

Background:

• Alemtuzumab is a monoclonal antibody targeting the CD52 antigen on lymphocytes.
• CD52 expression is found on both malignant and normal T and B cells.
• Alemtuzumab induces antitumor and immunosuppressive effects.

Purpose of the Study:

• To review the efficacy and safety of alemtuzumab in various hematologic malignancies.
• To provide guidance for optimizing alemtuzumab's clinical use.
• To synthesize current evidence on alemtuzumab's expanded therapeutic applications.

Main Methods:

• Literature review of alemtuzumab's clinical applications.
• Evaluation of efficacy and safety data across different hematologic conditions.
• Synthesis of evidence for clinical practice guidance.

Main Results:

• Alemtuzumab is approved for B-cell chronic lymphocytic leukemia (B-CLL).
• Its applications have expanded to lymphoma, acute leukemia, myelodysplastic syndromes (MDS), aplastic anemia (AA), graft-versus-host disease (GVHD), and CAR-T therapy.
• Evidence supports its efficacy and safety in these expanded indications.

Conclusions:

• Alemtuzumab is a versatile therapeutic agent for hematologic malignancies.
• Optimized use requires understanding its efficacy and safety profile in diverse conditions.
• Further clinical guidance is needed to maximize alemtuzumab's benefits.